Yash Suri

Yash Suri

Auto-generated profile, based on publicly available information

Yash Suri

College of Medicine, University of Arizona, Tucson, AZ, United States of America

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
YSYash Suri
Yash Suri
JYJonathan Parham Yasmeh
Jonathan Parham Yasmeh
Arnab BasuArnab Basu
Arnab Basu
Multiple studies have confirmed a high prevalence of prognostic germline mutations in prostate cancer. In recognition, the NCCN guidelines and recommendations for genetic counselling (GC) in prostate cancer patients were expanded. Data on prostate cancer patients at a single tertiary cancer center from January 2019 - June 2019 were queried. The cohort of patients from the queried list were evaluated for their eligibility for genetic testing. From the patients that were eligible for testing, the rate of referrals was ascertained. A 10-item questionnaire was concurrently sent to providers to understand germline genetic testing patterns and potential barriers. Only 39% of the eligible prostate cancer patients were referred, with testing completed in 11% with indications. 30% of providers reported they would be comfortable completing genetic counseling themselves. The identified barriers to provide genetic testing themselves were lack of time and expertise (50%). Other barriers included: lack of genetic counselor workforce (70%), lack of knowledge of genetic testing and the inadequate co-ordination of referrals (60%). In this retrospective study, many patients met the criteria for GC, however, the referrals for this patient population are inconsistent, and only a handful of the eligible patients completed testing. Identified barriers were provider's knowledge and comfort with guidelines and testing, systemic bottlenecks such as limited capacity of genetic counsellors, and the creation of improved workflows.

25 July 2024 in Journal of Bone and Joint Infection
Verified
Journal Article
Open access
PDF file
WEWilliam Estes
William Estes
LLL. Daniel Latt
L. Daniel Latt
JDJacob Robishaw Denton
Jacob Robishaw Denton
MRMatthew L. Repp
Matthew L. Repp
YSYash Suri
Yash Suri
TRTalha Riaz
Talha Riaz
Background: Coccidioidomycosis is a fungal infection endemic to the southwestern United States. Musculoskeletal manifestations are uncommon and seen in disseminated disease. While the involvement of the axial skeleton has been well described, the literature is limited on diseases involving the lower extremity. Methods: We identified three patients, at two regional academic medical centers in southern Arizona, who demonstrated different manifestations of osteoarticular coccidioidomycosis involving the lower extremity. Results: Case 1 is a 41-year-old male, with a history of HIV/AIDS and vertebral coccidioidomycosis, who presented with abscesses in the left hemipelvis and left proximal femoral osteomyelitis. He was treated with staged surgical debridement, including the use of amphotericin B impregnated beads. He remains on indefinite oral posaconazole suppression. Case 2 is a 46-year-old female, who presented with suspected right knee osteoarthritis. An MRI revealed septic arthritis and osteomyelitis. Necrotic bone was debrided, and synovial fluid cultures were positive for Coccidioides. She underwent a resection of the native knee joint with the insertion of an amphotericin B and voriconazole impregnated spacer. She continues oral itraconazole and awaits a total knee arthroplasty. Case 3 is a 76-year-old male, who presented with a draining right heel ulcer. Radiographs revealed bony destruction consistent with Charcot arthropathy. Irrigation and debridement revealed the gelatinous destruction of the talus and calcaneus, and cultures confirmed Coccidioides infection. A polymethyl methacrylate voriconazole spacer was placed. He subsequently underwent arthrodesis and remains on lifelong fluconazole. Conclusion: Lower-extremity osteoarticular coccidioidomycosis has various debilitating presentations that frequently mimic non-infectious etiologies. Treatment warrants surgical debridement, and prolonged antifungal therapy should be considered.

17 August 2022 in Cancer Medicine
Verified
Journal Article
Open access
OGOlumide Gbolahan
Olumide Gbolahan
NHNeda Hashemi‐Sadraei
Neda Hashemi‐Sadraei
SYSuri Yash
Suri Yash
GWGrant Williams
Grant Williams
RRRekha Ramachandran
Rekha Ramachandran
LNLisle Nabell
Lisle Nabell
Background: Given the dearth of data regarding the time to treatment initiation (TTI) in the palliative setting, and its impact on survival outcomes, we sought to determine TTI in a real‐world cohort of metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer (mPC) patients and evaluate the impact of TTI on real‐world survival outcomes.Methods: We collected survival and treatment data for mCRC and mPC from the Flatiron Health electronic health records (EHR) derived database. We divided TTI into 3 categories: < 2 weeks, 2–< 4 weeks, and 4–8 weeks, from diagnosis to first‐line therapy. Outcome measures were median TTI, real‐world overall survival (RW‐OS) based on TTI categories by Kaplan–Meier method, and impact of TTI on survival using cox proportional hazard models.Results: Among 7108 and 3231 patients with mCRC and mPC treated within 8 weeks of diagnosis, the median TTI were 28 days and 20 days. Median RW‐OS for mCRC was 24 months; 26.9 months versus 22.6 and 18.05 months in the 4–8‐week, 2–< 4 week (control) and < 2‐week groups, respectively (p < 0.0001). For mPC, median RW‐OS was 8 months, without significant difference in RW‐OS among the groups (p = 0.05). The 4–8‐week group was associated with lower hazard of death (HR 0.782, 95% CI 0.73–0.84, p < 0.0001) and the < 2‐week group was associated with a higher hazard of death (HR 1.26, 95% CI 1.15–1.38, p < 0.0001) in mCRC. The 4–8‐week group was associated with lower hazard of death for mPC (HR 0.88, 95% CI 0.8–0.97, p = 0.0094).Conclusion: In a real‐world cohort of patients treated within 8 weeks of diagnosis, and with the limitations of a retrospective study, later TTI did not have a negative impact on survival outcomes in mCRC and mPC.

1 August 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
COChinedum O. Ojinnaka
Chinedum O. Ojinnaka
YSYash Suri
Yash Suri

1 September 2022 in Families, Systems, & Health
Verified
Journal Article
Closed access
MMMatthew Martin
Matthew Martin
MMMindy L. McEntee
Mindy L. McEntee
DMDaniel Mullin
Daniel Mullin
YSYash Suri
Yash Suri
CEConstance van Eeghen
Constance van Eeghen
Purpose: Although many primary care clinics screen for behavioral health (BH) conditions using validated tools, it is not clear whether adult BH screening leads to better patient outcomes. Our objective was to determine the evidence base by reviewing effectiveness research for multiple strategies of BH screening in adult primary care identified in the Practice Integration Profile. Method: We conducted five rapid reviews of effectiveness research supporting BH screening strategies cited in the Practice Integration Profile. Each rapid review was conducted using an adapted REAL (Rapid Evidence Assessment of the Literature) methodology and a standardized search tailored for each screening strategy to identify evidence related to BH screening in primary care. Results: The database search yielded 931 references. Following eligibility review and extraction, we evaluated data from 20 references examining five screening strategies. Results demonstrated limited support for all five strategies and high risk of bias within most studies. Outcomes associated with various BH screening strategies were rarely the focus of study. Conclusions: There is an absence of robust, well-structured evidence supporting many of the BH screening strategies advocated for in primary care. Stakeholders may wish to understand how to ensure value when developing a robust screening program that will improve patient health outcomes. Future research should advance the science of BH screen selection, timing, and implementation by answering new questions about screening strategies. Public Significance Statement Primary care clinicians play an important role in screening patients for unmet health needs, including behavioral health concerns. Given the broad array of potential conditions that can be identified in primary care, the ability to focus on screening strategies with the greatest potential to improve patient-centered outcomes is a meaningful advance in care. The results of our rapid reviews suggest that although screening strategies were found to be important components in some studies, additional research is needed to identify evidence-based screening strategies.